Clobetasone butyrate, a new topical corticosteroid: clinical activity and effects on pituitary-adrenal axis function and model of epidermal atrophy.
Clobetasone butyrate is a new corticosteroid, selected for study because of its combination of good activity in the vasoconstriction test and low systemic activity in animals. Formulated as an 0.05% ointment and cream (Molivate) it was clinically effective in patients with eczema, its activity being significantly greater than that of hydrocortisone 1% or fluocortolone 0.2% (Ultradil). Under conditions that predispose to maximal percutaneous absorption clobetasone butyrate ointment had minimal effect on hypothalamic-pituitary-adrenal function. In an animal model of cutaneous atrophy it caused less thinning of the epidermis than steroids other than hydrocortisone. Clobetasone butyrate 0.05% ointment and cream gave every indication of offering clinically effective topical anti-inflammatory activity with a wide margin of safety.
D000287:Administration, Topical; D000818:Animals; D001623:Betamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D002990:Clobetasol / Q000031:analogs & derivatives; D003366:Cosyntropin; D004485:Eczema / Q000188:drug therapy; D005448:Fluocortolone / Q000627:therapeutic use; D006801:Humans; D007328:Insulin; D010912:Pituitary-Adrenal Function Tests; D010913:Pituitary-Adrenal System / Q000187:drug effects*; D011565:Psoriasis / Q000188:drug therapy; D012867:Skin / Q000187:drug effects; D013552:Swine
D007328:Insulin; D003366:Cosyntropin; D005448:Fluocortolone; C010893:clobetasone butyrate; D001623:Betamethasone; D002990:Clobetasol